Periodic Reporting for period 1 - MetaMacNiche (Unravelling the cell-cell circuits underlying the functional reprogramming of KCs and TAMs during liver metastasis)
Reporting period: 2023-11-01 to 2025-10-31
Macrophages are the most abundant immune population in many cancers. Kupffer cells are the resident macrophages of the liver are the first cells to interact with metastatic cells due to their location in the liver sinusoids. Additionally, monocyte-derived macrophages are also rapidly recruited as metastatic cells are spreading to the liver, and will constitute the tumor-associated macrophages (TAMs). The distinct role of Kupffer cells and TAMs in metastatic spreading and anti-cancer immune response have been studied in the past but showed conflicting results. Macrophages in cancer do not form a homogenous cell populations and can be wired to perform various functions, either promoting or inhibiting anti-cancer immunity. Our group, and other have shown that macrophage function is dictated not only by intrinsic factor, but also by signals delivered by their surrounding cells (ie fibroblasts, endothelial cells, cancer cells…), defining the macrophage niche. Using unique tracking tools developed in our lab, as well as cutting-edge omics and spatial technologies, this project aims at deciphering the cross-talk between macrophages and their niche, the consequences on macrophage polarization and immunotherapy response, as well as identifying novel therapeutic targets that can modulate tumor macrophage activation.
To get deeper insights regarding the contribution of the different macrophage subset to metastatic growth and the local immune response, depletion models were used to target specifically Kupffer cells or TAMs. Although no major effect was observed on tumor growth, different tumor organization were observed, underlying the facts that macrophages are a key player of the tumor micro-environment but their functional reprogramming rather than their deletion would efficiently improve tumor clearance. As a first step towards this direction, a novel in vivo CRISPR pipeline was used to knock-down specific receptors on Kupffer cells and TAMs.
Additionally, the effect of in vivo anti-PD1 treatment on the macrophage populations was also evaluated. Although there was no strong effect on tumor growth, as expected from the literature, the co-localization between macrophages and T cells appear to be changed.
The development of the in vivo CRISPR pipeline, and its optimization for cancer setting, already showed its feasibility and will prove valuable in the future to remove more receptors from the different macrophage populations and evaluate the impact on metastatic growth. Combining conventional immunotherapy, such as anti-PD1 blocking antibodies, with the in vivo CRISPR approach will allow us to remove the brakes hindering immunotherapy efficacy.
The extensive datasets generated thanks to this fellowship, including single-cell RNA sequencing, spatial transcriptomics and spatial proteomics are not only useful to this project but will also be useful to the host lab and the rest of the scientific community to address many more questions about the cells composing the metastatic niche.